ArticleClinical rheumatology2021
Correction to: How do patients define Raynaud's phenomenon? Differences between primary and secondary disease.
Susan L Murphy, Alain Lescoat, Mary Alore, Michael Hughes, John D Pauling, Maya Sabbagh, Dinesh Khanna
Abstract readPublished Erratum
In one paragraphArticle in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors.
Susan L MurphyDepartment of Physical Medicine and Rehabilitation, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M Suite 3100, Ann Arbor, MI, 48105, USA. sumurphy@umich.edu.ORCID https://orcid.org/0000-0001-7924-0012 Alain LescoatDepartment of Internal Medicine and Clinical Immunology, CHU Rennes, University of Rennes 1, Rennes, France.
Mary AlorePeer Mentors Program, University of Michigan Scleroderma Program, 7C27 NIB 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
Michael HughesDepartment of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
John D PaulingRoyal National Hospital for Rheumatic Diseases (at Royal United Hospitals), Bath, UK.
Maya SabbaghPeer Mentors Program, University of Michigan Scleroderma Program, 7C27 NIB 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.
Dinesh KhannaDepartment of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, 7C27 NIB 300 North Ingalls Street, Ann Arbor, MI, 48109, USA.ORCID https://orcid.org/0000-0003-1412-4453 Funding
Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6MSystemic Sclerosis-Associated Interstitial Lung Disease Response IndexR01AR070470 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2017 to 2019
$642kSyk blockade in bullous skin diseasesR43AR063129 · NIAMS · PORTOLA PHARMACEUTICALS, INC. · PI SINHA, UMA · 2012 to 2012
$298kNIAMS NIH HHS K24 AR063120NIAMS NIH HHS R01 AR070470NIAMS NIH HHS R43 AR063129
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID33547561
PMCPMC10734887
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390